Krystal Biotech (KRYS) EBIT (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of EBIT data on file, last reported at $53.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 48.1% year-over-year to $53.7 million; the trailing twelve-month figure through Mar 2026 stood at $178.6 million (up 64.4% YoY), and the FY2025 full-year result was $161.3 million, up 145.32% from the prior year.
• EBIT climbed to $53.7 million in Q1 2026, from $44.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $53.7 million in Q1 2026 to a low of -$50.2 million in Q1 2022.
• A 5-year average of $1.5 million and a median of $3.2 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT slumped 249.91% in 2022 and surged 1173.86% in 2024, its largest moves.
• Tracing KRYS's EBIT over 5 years: stood at -$34.8 million in 2022, then soared by 109.34% to $3.2 million in 2023, then surged by 1173.86% to $41.4 million in 2024, then grew by 7.0% to $44.3 million in 2025, then advanced by 21.28% to $53.7 million in 2026.
• Business Quant data shows KRYS's EBIT at $53.7 million in Q1 2026, $44.3 million in Q4 2025, and $41.4 million in Q3 2025.